Marloes Verstappen (M Verstappen)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Topics

Rheumatoid Arthritis

Monoclonal Antibody

Replacement Therapy

Disease Activity

Top Venues

Annals of the rheumatic diseases

Rheumatology (Oxford, England)

Arthritis research & therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah J H Khidir, Bastiaan T van Dijk, Doortje Isabelle Krijbolder, Marloes Verstappen, Elise van Mulligen, Annette H M van der Helm van Mil
Joint involvement in RA starts predominantly in the hands: functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA. RMD open 9 (2) (2023)
Anna M P Boeren, Marloes Verstappen, Agnes E M Looijen, Pascal Hendrik Pieter de Jong, Annette H M van der Helm van Mil
Rheumatoid arthritis presenting with mono- or oligo-arthritis and high VAS remains most fatigued during 5-years follow-up. Rheumatology (Oxford, England) (2023)
Cleo Rogier, Giulia Frazzei, Marion C Kortekaas, Marloes Verstappen, Sarah Ohrndorf, Elise van Mulligen, Ronald F Van Vollenhoven, Dirkjan van Schaardenburg, Pascal Hendrik Pieter de Jong, Annette H M van der Helm van Mil
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis? Rheumatology (Oxford, England) 61 (12) (2022)
Nikolet K den Hollander, Marloes Verstappen, Thomas Wj Huizinga, Annette H M van der Helm van Mil
Management of contemporary early undifferentiated arthritis: data on EULAR's recommendation on the risk of persistent disease. Annals of the rheumatic diseases 81 (5) (2022)
Quirine A Dumoulin, Marloes Verstappen, Annette H M van der Helm van Mil, Hanna W van Steenbergen
Joint Damage Over Time in Patients With Early Rheumatoid Arthritis Follows Trajectories Related to Distinct Courses of Disease Activity. The Journal of rheumatology (2022)
Marloes Verstappen, Thomas Wj Huizinga, Annette Hm van der Helm-van Mil
No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years. Annals of the rheumatic diseases 81 (8) (2022)
Marloes Verstappen, H W van Steenbergen, P H P de Jong, A H M van der Helm-van Mil
Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution. Arthritis research & therapy 24 (1) (2022)
Marloes Verstappen, Elise van Mulligen, P H P de Jong, Annette H M van der Helm van Mil
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability. RMD open 6 (1) (2021)
Fenne Wouters, Marc P Maurits, Laurette van Boheemen, Marloes Verstappen, Kulveer Mankia, Xanthe Marijn Edmée Matthijssen, Annemarie L Dorjée, Paul Emery, Rachel Knevel, Dirkjan van Schaardenburg, René E M Toes, Annette H M van der Helm van Mil
Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Annals of the rheumatic diseases (2021)
Marloes Verstappen, E Niemantsverdriet, X M E Matthijssen, S le Cessie, A H M van der Helm-van Mil
Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. Arthritis research & therapy 22 (1) (2020)